UBS Group Cuts Qiagen (NYSE:QGEN) Price Target to $48.00

Qiagen (NYSE:QGEN) had its price target cut by UBS Group from $50.00 to $48.00 in a report released on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s target price suggests a potential upside of 17.22% from the stock’s previous close.

QGEN has been the subject of a number of other reports. Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. Morgan Stanley reissued an “equal weight” rating and set a $46.67 target price (down from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Jefferies Financial Group reissued a “buy” rating and set a $52.50 target price (up from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. Finally, HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $47.64 target price for the company. in a research note on Thursday, October 17th. Five analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $49.84.

Qiagen Trading Down 3.5 %

QGEN stock traded down $1.49 during midday trading on Friday, hitting $40.95. 353,405 shares of the company’s stock were exchanged, compared to its average volume of 1,196,722. The business has a 50-day simple moving average of $43.80 and a two-hundred day simple moving average of $43.25. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $9.08 billion, a PE ratio of 102.03, a P/E/G ratio of 3.10 and a beta of 0.36. Qiagen has a 1-year low of $40.15 and a 1-year high of $49.30.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a return on equity of 13.43% and a net margin of 4.73%. On average, sell-side analysts predict that Qiagen will post 2.23 EPS for the current fiscal year.

Institutional Trading of Qiagen

A number of institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP lifted its holdings in shares of Qiagen by 77.7% in the 3rd quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock valued at $963,386,000 after purchasing an additional 9,293,040 shares during the last quarter. Victory Capital Management Inc. increased its position in Qiagen by 62.6% during the 3rd quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock worth $117,329,000 after purchasing an additional 991,325 shares during the period. State Street Corp increased its position in Qiagen by 3.9% during the 3rd quarter. State Street Corp now owns 2,380,008 shares of the company’s stock worth $108,457,000 after purchasing an additional 90,181 shares during the period. Allspring Global Investments Holdings LLC increased its position in Qiagen by 0.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,336,160 shares of the company’s stock worth $104,006,000 after purchasing an additional 16,072 shares during the period. Finally, Barclays PLC increased its position in Qiagen by 170.6% during the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock worth $84,259,000 after purchasing an additional 1,165,594 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.